FDA threatens seizure and injunction over compounded GLP-1 marketing

The U.S. Food and Drug Administration said on February 6, 2026 that it intends to take "decisive steps" to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to approved medicines ^[1]. In a statement from Commissioner Martin A. Makary, M.D., M.P.H., the agency named Hims & Hers along with "other compounding pharmacies" ^[1].

The statement frames the action as consumer protection. The FDA said the steps are "aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy," and added that the agency takes "seriously any potential violations of the Federal Food, Drug, and Cosmetic Act" ^[1].

What the FDA says companies can't claim

The second part of the announcement targets advertising. The FDA said it is taking steps to combat misleading direct-to-consumer advertising and marketing, following warning letters the agency sent in the fall of 2025 ^[1].

The statement lists three specific claims companies cannot make in promotional materials about non-FDA-approved compounded products ^[1]:

• that the products are generic versions of, or the same as, drugs approved by the FDA;
• that the compounded drugs use the same active ingredient as the FDA-approved drugs;
• that the compounded drugs are clinically proven to produce results for the patient.

Those are marketing lines that have been common across telehealth and compounding websites selling copies of semaglutide (the molecule in Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound). The FDA's February 6 statement does not name individual molecules or brands; it refers to "GLP-1" products generally ^[1].

The enforcement threat

The agency said it "will use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns" ^[1]. It went further with a direct warning: entities that manufacture, distribute or market unapproved compounded GLP-1 products "should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction" ^[1].

Seizure and injunction are court-backed actions. A seizure removes products from the market; an injunction is a court order that can stop a company from continuing a practice. The FDA statement does not say whether any specific case has been filed, against whom, or when ^[1].

Several practical details are not in the FDA's announcement. It does not spell out the legal mechanism it will use to restrict GLP-1 APIs, whether that involves imports, domestic bulk suppliers, or both; it does not give an effective date or a compliance deadline; and it does not say how many companies received the fall 2025 warning letters or what those letters said ^[1]. The statement also does not include any response from Hims & Hers ^[1].

Why it matters for patients

Many people in the U.S. have been buying compounded semaglutide or tirzepatide through telehealth platforms, often at lower monthly prices than branded products. The FDA is signaling that the supply chain for the raw ingredients behind those products, and the ads that sell them, are both now enforcement targets ^[1].

If the agency follows through, patients using mass-marketed compounded GLP-1 products could see supply or marketing changes at the companies that sell them. How quickly that happens, and which sellers are affected, is not yet known from the announcement ^[1].

The advertising rules also change what shoppers can expect to read. Under the FDA's statement, a compounded GLP-1 cannot be marketed as a generic or as "the same as" an approved drug, cannot be described as using the same active ingredient as the approved drug, and cannot be advertised as clinically proven to work ^[1]. The agency's core point is that it cannot verify the quality, safety or efficacy of these products ^[1].

What happens next

The FDA has stated intent, not a finished rule or a filed case. Warning letters went out in fall 2025 ^[1]; the February 6, 2026 statement says legal action may follow "without further notice" ^[1]. No further dated milestones are given in the announcement.

The FDA's byline on the statement lists Makary's tenure as Commissioner of Food and Drugs as April 2025 to May 2026 ^[1]. Whether this initiative continues under a successor is not addressed in the source.